Developer docs
API playgroundTry for free, no card

Search company profiles

Solve ME

Full company profile

uuid000jodb

Namestring
Solve ME
Legal namestring
Solve ME/CFS Initiative
Websiteurl
solvecfs.org
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Solve ME/CFS Initiative (DBA: Solve M.E.) is a 501(c)(3) nonprofit organization founded in 1987 and headquartered in Glendale, California. Its mission is to educate policymakers and accelerate research aimed at transforming the understanding of post-viral neuroimmune diseases, principally Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and, since 2020, Long Covid. The organization operates a portfolio of research-funding programs, including the Ramsay Research Grants and the Solve ME/CFS Catalyst Awards, which competitively allocate seed capital to academic investigators. Its technology footprint centers on the You + ME Registry and Biobank, a patient registry and biobank platform that collects longitudinal health data and biological samples from the ME/CFS community to support external research, alongside the ME/CFS Impact Tool for patient symptom tracking. Content products include the bi-annual Research 1st publication and The Chronicle journal, supported by an educational webinar series and a multi-channel media operation (social, blog, earned media). Distribution of services occurs directly through the organization's website, annual Advocacy Week events on Capitol Hill, the EmPOWER M.E. advocacy program, and co-founded coalitions — notably the Long COVID Alliance (450+ organizations) and the World ME Alliance (27 organizations).

Solve M.E. is funded entirely through charitable contributions rather than commercial revenue. Donation channels include one-time gifts, monthly giving, planned giving and bequests, workplace giving and matching-gift programs (CFC designation 10598), gifts of appreciated securities, charitable remainder and lead trusts, and DAF/IRA distributions. The organization does not charge for its educational, registry, or advocacy services. Its customer base comprises three principal stakeholder segments: patients and caregivers (primary recipients of resources, community, and registry participation), medical providers (recipients of clinical guidance and education), and researchers and scientists (recipients of grant funding, biospecimens, and registry data). The organization has no subsidiaries, no parent company, and operates with a remote staff structure adopted in March 2020, with formal leadership provided by CEO Emily Taylor and Chief Scientific Officer Sadie Whittaker.

Short descriptiontext

Solve M.E. is a 501(c)(3) nonprofit founded in 1987 that funds peer-reviewed ME/CFS and Long Covid research, operates the You + ME patient registry and biobank, and advocates for federal policy and funding on behalf of patients, caregivers, clinicians, and researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGlendale, United States
HQ citystring
Glendale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
disease research funding, patient advocacy services, ME/CFS research, Long Covid research, patient registry platform
Industry3 codes
1BPAGAKAL
CodeBPAGAKALPrimaryYes
2HLAJAKAN
CodeHLAJAKANPrimaryNo
3BPAHALAN
CodeBPAHALANPrimaryNo
NAICS code2 codes
  • 813212
  • 5417
SIC code1 code
  • 8731
Product category
Nonprofit Disease Research and Advocacy
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Donations and Fundraising
TypeGrants Donations
Description

Solve M.E. relies on charitable donations from patients, family members, and supporters to fund its operations, research grants, and advocacy programs. The organization offers multiple giving options including one-time donations, monthly giving, and DIY fundraising.

solvecfs.org
2Planned Giving
TypeLicensing Royalties
Description

Bequests and beneficiary designations under wills, trusts, life insurance policies, commercial annuities, and retirement plans allow donors to include Solve M.E. in their estate planning.

solvecfs.org
3Workplace Giving Programs
TypeGrants Donations
Description

Corporate workplace giving programs including matching gifts, Combined Federal Campaign (CFC designation 10598), state and municipal campaigns, and United Way Donor Option programs enable employees to contribute through payroll deduction.

solvecfs.org
4Gifts of Appreciated Securities
TypeGrants Donations
Description

Donors can make gifts of marketable securities, which are sold promptly upon receipt unless otherwise directed, allowing tax-advantaged charitable contributions.

solvecfs.org
5Charitable Remainder and Lead Trusts
TypeLicensing Royalties
Description

Donors can designate Solve M.E. as remainder or income beneficiary of charitable remainder trusts and charitable lead trusts for planned giving purposes.

solvecfs.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Ramsay Research Grants
Description

Research grant program named after Dr. Donald Ramsay, providing competitive funding for ME/CFS researchers to advance scientific understanding of the disease.

solvecfs.org
+4 more records
Core offering1 text field

Solve ME is a nonprofit organization that funds peer-reviewed scientific research into ME/CFS and Long Covid through competitive grant programs (Ramsay Research Grants and Catalyst Awards), operates the You + ME Registry and Biobank to collect patient health data and biospecimens, drives federal advocacy and policy change to expand research funding, and delivers educational resources and advocacy programs for patients, caregivers, healthcare providers, and researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Helped secure $105M in Long COVID research funding
+5 more records
Product overview1 text field

Solve ME/CFS Initiative is a nonprofit research organization rather than a technology product company. Its offerings consist of research funding programs (Ramsay Research Grants, Catalyst Awards), patient registry platforms (You + ME Registry), assessment tools (ME/CFS Impact Tool), educational publications (Research 1st, The Chronicle), and advocacy programs (EmPOWER M.E., Advocacy Week). The organization focuses on advancing ME/CFS and Long Covid research through grant funding, patient data collection, and community engagement rather than developing commercial software products.

Product and service7 records
1You + ME Registry and Biobank
CategoryPatient Registry and Biobank
Description

A patient registry and biobank for the ME/CFS community that enables patients to contribute their health data and biological samples to advance research into ME/CFS and related conditions. It collects self-reported health data and biospecimens from ME/CFS patients and serves as a research resource for scientists studying the disease.

2Ramsay Research Grants
CategoryResearch Grant Program
Description

Competitive peer-reviewed research grants funding scientific studies into the causes, treatments, and potential cures for ME/CFS. The program supports academic and clinical research teams investigating the disease.

3Solve ME/CFS Catalyst Awards
CategoryResearch Grant Program
Description

Funding awards to advance promising ME/CFS and Long Covid research toward clinical trials, including support for novel treatment approaches and diagnostic tools. The first Catalyst Award was issued to Dr. Akiko Iwasaki at Yale School of Medicine for research into biological drivers of Long Covid.

4ME/CFS Impact Tool
CategoryPatient Assessment Tool
Description

An assessment tool that helps patients track and measure the impact of ME/CFS symptoms on their daily lives. It is offered as part of the You + ME Registry platform for patient self-monitoring.

5Research 1st Publication
CategoryResearch Publication
Description

A bi-annual research publication providing updates on ME/CFS scientific findings, advocacy efforts, and community news.

6The Chronicle
CategoryResearch Publication
Description

Solve ME's flagship research and advocacy journal published to keep stakeholders informed about developments in ME/CFS research.

7EmPOWER M.E.
CategoryAdvocacy Program
Description

An advocacy initiative that empowers patients and advocates to take action for ME/CFS awareness and research funding, including EmPOWER M.E. roundtables and related advocacy events.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2021-07-01
Description

Solve M.E. partnered with Marked By COVID for COVID Lobby Days in Washington, D.C. (July 26-28, 2021) to advocate for federal action on COVID-19 research and support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Solve M.E. co-founded the Long COVID Alliance (LCA), a network of patient-advocates, scientists, disease experts, and drug developers who have joined together to leverage collective knowledge and resources to educate policy makers and accelerate research on post-viral illness. The alliance includes over 450 organizations and individuals.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-03-01
Description

Solve M.E. partnered with UCLA's Iris Cantor Women's Health Center to issue an ME/CFS-specific funding announcement through their Annual Health Pilot Program. This partnership opens up access to a major research network within the University of California system with a track record of obtaining approximately $27 million in follow-on NIH grants from $1 million invested.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2020-03-01
Description

Solve M.E. partnered with the American Lung Association to host an expert webinar on Coronavirus Preparedness for People with Chronic Diseases, featuring Dr. Albert Rizzo, Chief Medical Officer at the American Lung Association.

5Australian Biobank and Registry
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-08-01
Description

Solve M.E. partnered with an international collaborative on the Australian Biobank and Registry project, which received a $1 million grant award to establish a comprehensive biobank and registry for ME/CFS research.

solvecfs.org
6World ME Alliance
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded by Solve M.E., the World ME Alliance is a global collaboration of 27 organizations working together to advance research and awareness for ME (Myalgic Encephalomyelitis).

solvecfs.org
7COVID Survivors for Change
Strategic tierMinorTypeGTM or Marketing Partner
Description

Solve M.E. is a proud partner of March to Remember events nationwide hosted by COVID Survivors for Change, a nationwide network of COVID-19 survivors and families advocating for lifesaving policies.

solvecfs.org
Strategic tierMinorTypeGTM or Marketing Partner
Description

Solve M.E. joined the Chronic Disease Coalition in marking July as 'Chronic Disease Month' to amplify patient voices and advocate for patient rights.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

amfAR is a large, established disease-focused research funder (HIV/AIDS) that uses peer-reviewed grantmaking, advocacy, and partnerships in a model structurally similar to Solve ME's approach for ME/CFS and Long Covid.

2Body Politic
TypeEmerging player
Description

Body Politic is a Long Covid patient-advocacy organization also active in the Long COVID Alliance, representing a peer in patient-led organizing that complements Solve ME's more institutionally focused work.

TypeBroad incumbent
Description

ALS Association is a well-established disease-focused nonprofit combining research funding, federal advocacy, and patient services, providing a comparable integrated operating model at greater scale than Solve ME.

TypeEmerging player
Description

Patient-Led Research Collaborative conducts Long Covid research and is a Long COVID Alliance co-member with Solve ME, representing an emerging grassroots research counterpart to Solve ME's larger institutional footprint.

TypeDirect peer
Description

Bateman Horne Center is a clinical care and research center for ME/CFS and Long Covid that combines patient care, provider education, and research in a model directly comparable to Solve ME's integrated research-and-advocacy approach.

TypeBroad incumbent
Description

Cystic Fibrosis Foundation is a mature disease-focused nonprofit that funds research, drives advocacy, and helped deliver FDA-approved therapies, making it a benchmark peer for Solve ME's long-term path from seed grants to approved treatments.

TypeDirect peer
Description

Open Medicine Foundation is the other leading private funder of ME/CFS and post-viral disease research, directly competing with Solve ME for donor dollars and researcher relationships in the same ME/CFS niche.

TypeRegional player
Description

Emerge Australia is the leading ME/CFS advocacy and research support organization in Australia, a regional peer whose disease focus and grantmaking-plus-advocacy model directly mirror Solve ME's approach.

TypeDirect peer
Description

The ME Association is a UK-based charity funding ME research and supporting patients, providing a comparable disease-focused nonprofit model even though it operates primarily in the UK.

TypeDirect peer
Description

#MEAction is a primary ME/CFS patient-advocacy organization running grassroots campaigns and policy work directly comparable to Solve ME's EmPOWER M.E. and Advocacy Week programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solve ME

Nonprofit Disease Research and Advocacysolvecfs.org

Solve M.E. is a 501(c)(3) nonprofit founded in 1987 that funds peer-reviewed ME/CFS and Long Covid research, operates the You + ME patient registry and biobank, and advocates for federal policy and funding on behalf of patients, caregivers, clinicians, and researchers.

What Solve ME does

Solve ME/CFS Initiative (DBA: Solve M.E.) is a 501(c)(3) nonprofit organization founded in 1987 and headquartered in Glendale, California. Its mission is to educate policymakers and accelerate research aimed at transforming the understanding of post-viral neuroimmune diseases, principally Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and, since 2020, Long Covid. The organization operates a portfolio of research-funding programs, including the Ramsay Research Grants and the Solve ME/CFS Catalyst Awards, which competitively allocate seed capital to academic investigators. Its technology footprint centers on the You + ME Registry and Biobank, a patient registry and biobank platform that collects longitudinal health data and biological samples from the ME/CFS community to support external research, alongside the ME/CFS Impact Tool for patient symptom tracking. Content products include the bi-annual Research 1st publication and The Chronicle journal, supported by an educational webinar series and a multi-channel media operation (social, blog, earned media). Distribution of services occurs directly through the organization's website, annual Advocacy Week events on Capitol Hill, the EmPOWER M.E. advocacy program, and co-founded coalitions — notably the Long COVID Alliance (450+ organizations) and the World ME Alliance (27 organizations).

Solve M.E. is funded entirely through charitable contributions rather than commercial revenue. Donation channels include one-time gifts, monthly giving, planned giving and bequests, workplace giving and matching-gift programs (CFC designation 10598), gifts of appreciated securities, charitable remainder and lead trusts, and DAF/IRA distributions. The organization does not charge for its educational, registry, or advocacy services. Its customer base comprises three principal stakeholder segments: patients and caregivers (primary recipients of resources, community, and registry participation), medical providers (recipients of clinical guidance and education), and researchers and scientists (recipients of grant funding, biospecimens, and registry data). The organization has no subsidiaries, no parent company, and operates with a remote staff structure adopted in March 2020, with formal leadership provided by CEO Emily Taylor and Chief Scientific Officer Sadie Whittaker.

Solve ME firmographics

Firmographics
Name
Solve ME
Legal name
Solve ME/CFS Initiative
Website
https://solvecfs.org
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
11–50 employees
Short description
Solve M.E. is a 501(c)(3) nonprofit founded in 1987 that funds peer-reviewed ME/CFS and Long Covid research, operates the You + ME patient registry and biobank, and advocates for federal policy and funding on behalf of patients, caregivers, clinicians, and researchers.
Ownership category
akta.pro rank

Where Solve ME is headquartered

Location

Headquarters

HQ city
Glendale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Solve ME business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Donations and Fundraising: Solve M.E. relies on charitable donations from patients, family members, and supporters to fund its operations, research grants, and advocacy programs. The organization offers multiple giving options including one-time donations, monthly giving, and DIY fundraising.
  2. Planned Giving: Bequests and beneficiary designations under wills, trusts, life insurance policies, commercial annuities, and retirement plans allow donors to include Solve M.E. in their estate planning.
  3. Workplace Giving Programs: Corporate workplace giving programs including matching gifts, Combined Federal Campaign (CFC designation 10598), state and municipal campaigns, and United Way Donor Option programs enable employees to contribute through payroll deduction.
  4. Gifts of Appreciated Securities: Donors can make gifts of marketable securities, which are sold promptly upon receipt unless otherwise directed, allowing tax-advantaged charitable contributions.
  5. Charitable Remainder and Lead Trusts: Donors can designate Solve M.E. as remainder or income beneficiary of charitable remainder trusts and charitable lead trusts for planned giving purposes.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Solve ME product offering

Product offering

Core offering

Solve ME is a nonprofit organization that funds peer-reviewed scientific research into ME/CFS and Long Covid through competitive grant programs (Ramsay Research Grants and Catalyst Awards), operates the You + ME Registry and Biobank to collect patient health data and biospecimens, drives federal advocacy and policy change to expand research funding, and delivers educational resources and advocacy programs for patients, caregivers, healthcare providers, and researchers.

Product overview

Solve ME/CFS Initiative is a nonprofit research organization rather than a technology product company. Its offerings consist of research funding programs (Ramsay Research Grants, Catalyst Awards), patient registry platforms (You + ME Registry), assessment tools (ME/CFS Impact Tool), educational publications (Research 1st, The Chronicle), and advocacy programs (EmPOWER M.E., Advocacy Week). The organization focuses on advancing ME/CFS and Long Covid research through grant funding, patient data collection, and community engagement rather than developing commercial software products.

Differentiator

Problem solved

Functional benefit

Brands

  • Ramsay Research Grants: Research grant program named after Dr. Donald Ramsay, providing competitive funding for ME/CFS researchers to advance scientific understanding of the disease.
  • Solve ME/CFS Catalyst Awards
  • You + ME Registry
  • EmPOWER M.E.
  • Long COVID Alliance

Products and services

  • You + ME Registry and Biobank A patient registry and biobank for the ME/CFS community that enables patients to contribute their health data and biological samples to advance research into ME/CFS and related conditions. It collects self-reported health data and biospecimens from ME/CFS patients and serves as a research resource for scientists studying the disease.
  • Ramsay Research Grants Competitive peer-reviewed research grants funding scientific studies into the causes, treatments, and potential cures for ME/CFS. The program supports academic and clinical research teams investigating the disease.
  • Solve ME/CFS Catalyst Awards Funding awards to advance promising ME/CFS and Long Covid research toward clinical trials, including support for novel treatment approaches and diagnostic tools. The first Catalyst Award was issued to Dr. Akiko Iwasaki at Yale School of Medicine for research into biological drivers of Long Covid.
  • ME/CFS Impact Tool An assessment tool that helps patients track and measure the impact of ME/CFS symptoms on their daily lives. It is offered as part of the You + ME Registry platform for patient self-monitoring.
  • Research 1st Publication A bi-annual research publication providing updates on ME/CFS scientific findings, advocacy efforts, and community news.
  • The Chronicle Solve ME's flagship research and advocacy journal published to keep stakeholders informed about developments in ME/CFS research.
  • EmPOWER M.E. An advocacy initiative that empowers patients and advocates to take action for ME/CFS awareness and research funding, including EmPOWER M.E. roundtables and related advocacy events.

Quantifiable outcome

  • Helped secure $105M in Long COVID research funding
  • +5 more outcomes

Companies that use Solve ME

Customer profile

Segments3 records

Ideal customer profiles4 records

Solve ME technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Solve ME partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and flagship.

  • Marked By COVIDminorGTM or Marketing Partner · 1 July 2021Solve M.E. partnered with Marked By COVID for COVID Lobby Days in Washington, D.C. (July 26-28, 2021) to advocate for federal action on COVID-19 research and support.
  • Long COVID AlliancecoreStrategic or Co-development Partner · 1 March 2021Solve M.E. co-founded the Long COVID Alliance (LCA), a network of patient-advocates, scientists, disease experts, and drug developers who have joined together to leverage collective knowledge and resources to educate policy makers and accelerate research on post-viral illness. The alliance includes over 450 organizations and individuals.
  • UCLA Iris Cantor Women's Health CenterflagshipStrategic or Co-development Partner · 1 March 2020Solve M.E. partnered with UCLA's Iris Cantor Women's Health Center to issue an ME/CFS-specific funding announcement through their Annual Health Pilot Program. This partnership opens up access to a major research network within the University of California system with a track record of obtaining approximately $27 million in follow-on NIH grants from $1 million invested.
  • American Lung AssociationminorGTM or Marketing Partner · 1 March 2020Solve M.E. partnered with the American Lung Association to host an expert webinar on Coronavirus Preparedness for People with Chronic Diseases, featuring Dr. Albert Rizzo, Chief Medical Officer at the American Lung Association.
  • Australian Biobank and RegistryflagshipStrategic or Co-development Partner · 1 August 2019Solve M.E. partnered with an international collaborative on the Australian Biobank and Registry project, which received a $1 million grant award to establish a comprehensive biobank and registry for ME/CFS research.
  • World ME AlliancecoreStrategic or Co-development PartnerCo-founded by Solve M.E., the World ME Alliance is a global collaboration of 27 organizations working together to advance research and awareness for ME (Myalgic Encephalomyelitis).
  • COVID Survivors for ChangeminorGTM or Marketing PartnerSolve M.E. is a proud partner of March to Remember events nationwide hosted by COVID Survivors for Change, a nationwide network of COVID-19 survivors and families advocating for lifesaving policies.
  • Chronic Disease CoalitionminorGTM or Marketing PartnerSolve M.E. joined the Chronic Disease Coalition in marking July as 'Chronic Disease Month' to amplify patient voices and advocate for patient rights.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Solve ME competitors and assessment

Company assessment

Broad incumbents

  • amfAR: amfAR is a large, established disease-focused research funder (HIV/AIDS) that uses peer-reviewed grantmaking, advocacy, and partnerships in a model structurally similar to Solve ME's approach for ME/CFS and Long Covid.
  • ALS Association: ALS Association is a well-established disease-focused nonprofit combining research funding, federal advocacy, and patient services, providing a comparable integrated operating model at greater scale than Solve ME.
  • Cystic Fibrosis Foundation: Cystic Fibrosis Foundation is a mature disease-focused nonprofit that funds research, drives advocacy, and helped deliver FDA-approved therapies, making it a benchmark peer for Solve ME's long-term path from seed grants to approved treatments.

Emerging players

  • Body Politic: Body Politic is a Long Covid patient-advocacy organization also active in the Long COVID Alliance, representing a peer in patient-led organizing that complements Solve ME's more institutionally focused work.
  • Patient-Led Research Collaborative: Patient-Led Research Collaborative conducts Long Covid research and is a Long COVID Alliance co-member with Solve ME, representing an emerging grassroots research counterpart to Solve ME's larger institutional footprint.

Direct peers

  • Bateman Horne Center: Bateman Horne Center is a clinical care and research center for ME/CFS and Long Covid that combines patient care, provider education, and research in a model directly comparable to Solve ME's integrated research-and-advocacy approach.
  • Open Medicine Foundation: Open Medicine Foundation is the other leading private funder of ME/CFS and post-viral disease research, directly competing with Solve ME for donor dollars and researcher relationships in the same ME/CFS niche.
  • ME Association: The ME Association is a UK-based charity funding ME research and supporting patients, providing a comparable disease-focused nonprofit model even though it operates primarily in the UK.
  • #MEAction: #MEAction is a primary ME/CFS patient-advocacy organization running grassroots campaigns and policy work directly comparable to Solve ME's EmPOWER M.E. and Advocacy Week programs.

Regional players

  • Emerge Australia: Emerge Australia is the leading ME/CFS advocacy and research support organization in Australia, a regional peer whose disease focus and grantmaking-plus-advocacy model directly mirror Solve ME's approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Solve ME social profiles

Digital presence

Solve ME financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solve ME leadership team

Management profile

Number of profiles

Profiles3 records

Solve ME funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solve ME M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solve ME

What does Solve ME do?

Solve ME is a nonprofit organization that funds peer-reviewed scientific research into ME/CFS and Long Covid through competitive grant programs (Ramsay Research Grants and Catalyst Awards), operates the You + ME Registry and Biobank to collect patient health data and biospecimens, drives federal advocacy and policy change to expand research funding, and delivers educational resources and advocacy programs for patients, caregivers, healthcare providers, and researchers.

Is Solve ME a public or private company?

Solve ME is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Solve ME founded?

Solve ME was founded in 1987. It employs 11 to 50 people.

Where is Solve ME based?

Solve ME is headquartered in Glendale, United States, in the North America region.

How does Solve ME make money?

Five revenue lines are on record. Donations and Fundraising is the primary driver. The others are planned Giving, workplace Giving Programs, gifts of Appreciated Securities and charitable Remainder and Lead Trusts.

Who are Solve ME's main competitors?

Broad incumbents on record are amfAR, ALS Association and Cystic Fibrosis Foundation. Emerging players are Body Politic and Patient-Led Research Collaborative. Direct peers are Bateman Horne Center, Open Medicine Foundation, ME Association and #MEAction. Emerge Australia is listed as a regional player.

Does Solve ME have an API?

No public API is recorded for Solve ME.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SolvecfsSolve M.E. Announces Catalyst Award To Study Therapeutic Devices for People with ME/CFS and Long CovidSolve M.E. announced funding for Renegade Research's SIGNAL study, a device lending library for ME/CFS and Long Covid patients. The study evaluates the Truvaga vagus nerve stimulation and Vielight red light therapy devices, with participants contributing longitudinal data. The award aims to establish a scalable framework for future device evaluations.PR NewswireSolve M.E. Announces Catalyst Award Funding To Renegade Research For the Study of Therapeutic Devices for People with ME/CFS and Long CovidSolve M.E. announced funding for Renegade Research's SIGNAL study, a device lending library for ME/CFS and Long Covid patients. The study evaluates the Truvaga vagus nerve stimulation and Vielight red light therapy devices, with participants contributing longitudinal data. The award aims to establish a scalable framework for future device evaluations.PR NewswireNew Research Funding From Solve M.E. Advances Innovative ME/CFS and Long Covid Studies Toward TreatmentsSolve M.E. announced new funding through its Catalyst Awards for two research studies aimed at accelerating diagnostics and treatments for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Covid. One study led by Dr. Jay H. Chung will test IVO-21, a low-cost pill medication, in preclinical mouse models to assess its effects on cellular energy and inflammation, while the DecodeME management team will expand a genetic study using whole genome sequencing to analyze participants' genetic data. The funding seeks to bridge the gap between research and clinical trials, addressing the current lack of FDA-approved treatments and definitive diagnostic tests for these complex, disabling illnesses affecting millions worldwide.MorningstarNew Research Funding From Solve M.E. Advances Innovative ME/CFS and Long Covid Studies Toward TreatmentsOn May 12, 2026, Solve M.E. announced new Catalyst Award funding for two research studies targeting ME/CFS and Long Covid diagnostics and treatments — one testing a low-cost mitochondrial stabilizer called IVO in preclinical mouse models, and another expanding the DecodeME genetic study with whole genome sequencing. The organization stated the awards aim to bridge funding gaps and accelerate promising research toward clinical trials, as no FDA-approved treatments currently exist for these complex disabling illnesses. The funded studies could advance efforts to identify biomarkers and biological pathways associated with these conditions.PR NewswireSolve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid BreakthroughsSolve M.E. announced funding for two pioneering studies through its ME/CFS Catalyst Awards to advance research into ME/CFS and Long Covid, both conditions lacking FDA-approved therapies. The first study will evaluate whether semaglutide—a GLP-1 receptor agonist—can improve symptoms and quality of life for ME/CFS patients receiving treatment for being overweight. The second study aims to identify specific proteins that trigger dysfunctional immune responses in ME/CFS and Long Covid, potentially paving the way for new diagnostic tools and targeted treatments.PR NewswireSolve M.E., Brain Inflammation Collaborative (BIC), ChronicleBio, Complex Disorders Alliance, and CareEvolution Launch Groundbreaking Partnership to Accelerate Research on ME/CFS, Long Covid, and IACCSolve M.E., the Brain Inflammation Collaborative (BIC), ChronicleBio, the Complex Disorders Alliance, and CareEvolution have launched a partnership to advance research on myalgic encephalomyelitis (ME)/chronic fatigue syndrome, Long Covid, and other infection-associated chronic conditions. The Brain Inflammation Collaborative will take over management of Solve M.E. 's Solve Together patient database platform and expand it to include pediatric populations and additional diagnoses, while ChronicleBio will leverage the data to fuel clinical trials. A full roll-out of the platform under BIC leadership is expected in 2025.PR NewswireSolve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIsSolve M.E. appointed Emily Taylor as its new President and CEO, succeeding Kristin Jacobson who resigned following medical leave. The organization also published a white paper urging the National Institutes of Health to restructure funding mechanisms for infection-associated chronic conditions like ME/CFS and Long Covid.PR NewswireSolve M.E. Awarded Grant From Chan Zuckerberg Initiative to Support Patient Engagement in Long Covid ResearchSolve M.E., a non-profit organization focused on ME/CFS and Long Covid, received a $247,500 grant from the Chan Zuckerberg Initiative to develop a program that trains patient leaders, scientists, and stakeholders to enhance patient engagement in Long Covid research. The funded program, called LC-PLAN (Long Covid Patient Leader Advancement Network), will create a curriculum to prepare patients for research advisory roles, including participation in FDA-hosted Patient Focused Drug Development meetings. Once completed, the training program will be made available to Long Covid patients, non-profit organizations, and researchers to establish patient-driven input at the outset of Long Covid research.PR NewswireSOLVE M.E. LAUNCHES THE FIRST NATIONWIDE PSA CAMPAIGN TO BROADEN AWARENESS OF LONG COVIDSolve M.E., a non-profit organization focused on post-infection diseases, has launched the first nationwide public service announcement campaign titled "How Long?" to raise awareness about Long Covid, which affects up to 30% of COVID-19 infected individuals and over 20 million Americans. The campaign, developed in partnership with the Entertainment Industry Foundation, aims to drive public and private investment in research for Long Covid and related conditions like ME/CFS, POTS, and MCAS, which currently have no approved treatments or diagnostic tests. The initiative builds on Solve M.E. 's prior advocacy work that helped secure $1.25 billion in NIH funding for Long Covid research and includes the Long Covid Alliance and Long Covid Registry.GlobeNewswireAIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022AIM ImmunoTech will participate in the Solve M.E. event on May 19, 2022, discussing its Ampligen product for ME/CFS and Long COVID. The company has dosed its first Long Hauler patient with Ampligen in an expanded access program. The event is virtual and in New York.